Abivax (ABVX) Provides Operational and Key Program Update

Go back to Abivax (ABVX) Provides Operational and Key Program Update

Abivax Provides Operational and Key Program Update

July 15, 2024 4:00 PM EDT

Abivax Provides Operational and Key Program Update

Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with... More